Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature.
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
revised:
08
07
2024
received:
22
02
2024
accepted:
10
07
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
30
7
2024
Statut:
aheadofprint
Résumé
Urothelial carcinoma (UC) demonstrates significant molecular and histologic heterogeneity. The WHO 2022 classification has hinted at adding molecular signatures to the morphologic diagnosis. As morphology and associated molecular repertoire may potentially translate to choices of and response to therapy and relapse rate, broader acceptability of recognizing these key features among uropathologists is needed. This prompted an international survey to ascertain the practice patterns in classical/subtype UC among uropathologists across the globe. A survey instrument was shared among 98 uropathologists using SurveyMonkey software. Anonymized respondent data were analysed. The response rate was 85%. A majority were in concordance with the profiles of luminal (93%) and basal (82%) types. Opinion on the FGFR3 testing platform was variable. While 95% concurred that TERT promoter mutation is the key driver in UC, 72% had the opinion that APOBEC mutagenesis is the main signature in muscle invasive bladder cancer (MIBC). Uropathologists have divergent opinions on MIBC and ERCC2 mutations. Among the participants, 94% would quantify aggressive micropapillary and sarcomatoid histology, while 88% would reevaluate another transurethral resection of the bladder tumour specimen in nonmuscle invasive tumour with micropapillary, small cell, or sarcomatoid histology. A leading number agreed to specific molecular signatures of micropapillary (93%), plasmacytoid (97%), and small cell (86%) subtypes. Ninety-six percent of participants agreed that a small-cell component portends a more aggressive course and should be treated with neoadjuvant chemotherapy and 63% would perform HER2/neu testing only on oncologist's request in advanced tumours. Ninety percent agreed that microsatellite instability testing, although not a standard protocol, should be considered in young patients with upper tract UC. Eighty-six percent agreed that UC with high tumour mutational burden would be a better candidate for immunotherapy. In the era of precision medicine, enhanced understanding of molecular heterogeneity of UC will contribute to better therapeutic options, novel biomarker discovery, innovative management protocols, and outcomes. Our survey provides a broad perspective of pathologists' perceptions and experience regarding incorporation of histomolecular approaches to "personalize" therapy. Due to variable clinical adoption, there is a need for additional data using uniform study criteria. This will drive generation of best practice guidelines in this area for widespread and consistent clinical utility.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Witjes JA, Bruins HM, Cathomas R et al. European Association of Urology guidelines on muscle‐invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur. Urol. 2021; 79; 82–104.
Babjuk M, Burger M, Compérat E et al. European Association of Urology guidelines on nonmuscle‐invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur. Urol. 2022; 81; 75–94.
Available at: https://gco.iarc.fr/today/data/factsheets/cancers/39‐All‐cancers‐fact‐sheet.pdf. (Accessed December 11, 2022).
Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374; 239–249.
Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2020; 68; 394–424.
Mohanty SK, Lobo A, Mishra SK, Cheng L. Precision medicine in bladder cancer: present challenges and future directions. J. Pers. Med. 2023; 13; 756.
National Comprehensive Cancer Network. Bladder cancer (Version 3.2023). https://www.nccn.org/professionals/physician_gls/pdf/bladder Accessed August 20, 2023.
Alexandrov LB, Nik‐Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013; 500; 415–421.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507; 315–322.
Ross JS, Wang K, Khaira D et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer 2016; 122; 702–711.
Al‐Ahmadie H, Iyer G. Updates on the genetics and molecular subtypes of urothelial carcinoma and select variants. Surg. Pathol. Clin. 2018; 11; 713–723.
WHO Classification of Tumors Editorial Board. Urinary and male genital tumors. Lyon, France: International Agency for Research on Cancer; 2022. (WHO classification of tumors series, 5th ed. vol. 8). (Accessed July 22, 2023).
Lopez‐Beltran A, Cheng L. Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum. Pathol. 2006; 37; 1371–1388.
Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod. Pathol. 2009; 22 Suppl2; S96–S118.
Tan TZ, Rouanne M, Tan KT, Huang RYJ, Thiery JP. Molecular subtypes of urothelial bladder cancer: results from a meta‐cohort analysis of 2411 tumors. Eur. Urol. 2019; 75; 423–432.
Zhao M, He XL, Teng XD. Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview. Chin. J. Cancer Res. 2016; 28; 92–98.
Crawford J. The origins of bladder cancer. Lab. Investig. 2008; 88; 686–693.
Cheng L, Davidson DD, Maclennan GT et al. The origins of urothelial carcinoma. Expert. Rev. Anticancer. Ther. 2010; 10; 865–880.
Kompier LC, Lurkin I, van der Aa MN et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010; 5; e13821.
Millis SZ, Bryant D, Basu G et al. Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clin. Genitourin. Cancer 2015; 13; e37–e49.
Zhu S, Yu W, Yang X, Wu C, Cheng F. Traditional classification and novel subtyping systems for bladder cancer. Front. Oncol. 2020; 10; 102.
Netto GJ, Cheng L. Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch. Pathol. Lab Med. 2012; 136; 372–390.
Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu. Rev. Pathol. 2009; 4; 251–285.
Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat. Rev. Cancer 2005; 5; 713–725.
Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol. 2006; 24; 5552–5564.
Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 2015; 15; 25–41.
Cheng L, Zhang S, Wang M, Lopez‐Beltran A. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. Hum. Pathol. 2023; 133; 56–75.
Lopez‐Beltran A, Cimadamore A, Montironi R, Cheng L. Molecular pathology of urothelial carcinoma. Hum. Pathol. 2021; 113; 67–83.
Günes C, Wezel F, Southgate J, Bolenz C. Implications of TERT promoter mutationsand telomerase activity in urothelial carcinogenesis. Nat. Rev. Urol. 2018; 15; 386–393.
Bell RJ, Rube HT, Xavier‐Magalhaes A et al. Understanding TERT promoter mutations: a common path to immortality. Mol. Cancer Res. 2016; 14; 315–323.
Borah S, Xi L, Zaug AJ et al. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 2015; 347; 1006–1010.
Chakravarti D, LaBella KA, DePinho RA. Telomeres: history, health, and hallmarks of aging. Cell 2021; 184; 306–322.
Jiang J, Wang Y, Sušac L et al. Structure of telomerase with telomeric DNA. Cell 2018; 173; 1179–1190.
Wan S, Liu X, Hua W, Xi M, Zhou Y, Wan Y. The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer. Bioengineered 2021; 12; 1495–1504.
Rachakonda PS, Hosen I, de Verdier PJ et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc. Natl. Acad. Sci. USA 2013;110:17426–17431.
Isharwal S, Audenet F, Drill E et al. Prognostic value of TERT alterations, mutational and copy number alterations burden in urothelial carcinoma. Eur. Urol. Focus 2019; 5; 201–204.
Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur. Urol. 2014; 65; 65–369.
Allory Y, Beukers W, Sagrera A et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur. Urol. 2014; 65; 360–366.
Robertson AG, Kim J, Al‐Ahmadie H et al. Comprehensive molecular characterization of muscle‐invasive bladder cancer. Cell 2017;171:540–564
Meeks JJ, Al‐Ahmadie H, Faltas BM et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat. Rev. Urol. 2020; 17; 259–270.
Nordentoft I, Lamy P, Birkenkamp‐Demtröder K et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep. 2014; 7; 1649–1663.
Moris A, Murray S, Cardinaud S. AID and APOBECs span the gap between innate and adaptive immunity. Front. Microbiol. 2014; 5; 534.
Roberts SA, Lawrence MS, Klimczak LJ et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 2013; 45; 970–976.
Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 2013; 45; 977–983.
Faltas BM, Prandi D, Tagawa ST et al. Clonal evolution of chemotherapy‐resistant urothelial carcinoma. Nat. Genet. 2016; 48; 14909.
Teo MY, Bambury RM, Zabor EC et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum‐treated advanced urothelial carcinoma. Clin. Cancer Res. 2017; 23; 3610–3618.
Teo MY, Seier K, Ostrovnaya I et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD‐1/PD‐L1 blockade in advanced urothelial cancers. J. Clin. Oncol. 2018; 36; 1685–1694.
Desai NB, Scott SN, Zabor EC et al. Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer 2016; 122; 3715–3723.
Van Allen EM, Mouw KW, Kim P et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle‐invasive urothelial carcinoma. Cancer Discov. 2014; 4; 1140–1153.
Mouw KW, D'Andrea AD. DNA repair deficiency and immunotherapy response. J. Clin. Oncol. 2018; 36; 1710–1713.
Lopez‐Beltran A, Blanca A, Cimadamore A, Gogna R, Montironi R, Cheng L. Molecular classification of bladder urothelial carcinoma using nanostring‐based gene expression analysis. Cancers (Basel) 2021; 13; 5500.
Necchi A, de Jong JJ, Raggi D et al. Molecular characterization of residual bladder cancer after neoadjuvant pembrolizumab. Eur. Urol. 2021; 80; 149–159.
Yoshida T, Kates M, Fujita K, Bivalacqua TJ, McConkey DJ. Predictive biomarkers for drug response in bladder cancer. Int. J. Urol. 2019; 26; 1044–1053.
Al‐Ahmadie H, Netto GJ. Updates on the genomics of bladder cancer and novel molecular taxonomy. Adv. Anat. Pathol. 2020; 27; 36–43.
Sjödahl G, Jackson CL, Bartlett JM et al. Molecular profiling inmuscle‐invasive bladder cancer: more than the sum of its parts. J. Pathol. 2019; 247; 563–573.
Damrauer JS, Hoadley KA, Chism DD et al. Intrinsic subtypes of high‐grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl. Acad. Sci. USA 2014; 111; 3110–3115.
Rodriguez Pena MDC, Chaux A, Eich ML et al. Immunohistochemical assessment of basal and luminal markers in nonmuscle invasive urothelial carcinoma of bladder. Virchows Arch. 2019;475:349–356.
Dadhania V, Zhang M, Zhang L et al. Meta‐analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 2016; 12; 105–117.
Choi W, Porten S, Kim S et al. Identification of distinct basal and luminal subtypes of muscle‐invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014; 25; 152–165.
Lerner SP, McConkey DJ, Hoadley KA et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer 2016; 2; 37–47.
Sjödahl G, Lauss M, Lövgren K et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 2012; 18; 3377–3386.
Sjödahl G, Lövgren K, Lauss M et al. Towarda molecular pathologic classification of urothelial carcinoma. Am. J. Pathol. 2013; 183; 681–691.
Sjödahl G, Eriksson P, Liedberg F, Höglund M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour‐cell phenotype classification. J. Pathol. 2017; 242; 113–125.
Kim B, Jang I, Kim K et al. Comprehensive gene expression analyses of immunohistochemically defined subgroups of muscle‐invasive urinary bladder urothelial carcinoma. Int. J. Mol. Sci. 2021; 22; 628.
Guo CC, Bondaruk J, Yao H et al. Assessment of luminal and basal phenotypes in bladder cancer. Sci. Rep. 2020; 10; 9743.
Jalanko T, de Jong JJ, Gibb EA, Seiler R, Black PC. Genomic subtyping in bladder cancer. Curr. Urol. Rep. 2020; 21; 9.
Kim J, Akbani R, Creighton CJ et al. Invasive bladder cancer: genomic insights and therapeutic promise. Clin. Cancer Res. 2015; 21; 4514–4524.
Lindgren D, Frigyesi A, Gudjonsson S et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 2010; 70; 3463–3472.
Marzouka NA, Eriksson P, Rovira C, Liedberg F, Sjödahl G, Höglund M. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci. Rep. 2018; 8; 3737.
Chang MT, Penson A, Desai NB et al. Small‐cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin. Cancer Res. 2018; 24; 1965–1973.
Hodgson A, Liu SK, Vesprini D, Xu B, Downes MR. Basal‐subtype bladder tumours show a ‘hot’ immunophenotype. Histopathology 2018; 73; 748–757.
Lopez‐Beltran A, Cimadamore A, Blanca A et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel) 2021;13:131.
Chang SS, Bochner BH, Chou R et al. Treatment of nonmetastatic muscle‐invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J. Urol. 2017; 198; 552–559.
Linder BJ, Boorjian SA, Cheville JC et al. The impact of histological reclassification during pathology re‐review–evidence of a Will Rogers effect in bladder cancer? J. Urol. 2013; 190; 1692–1697.
Hansel DE, Amin MB, Comperat E et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur. Urol. 2013; 63; 321–332.
Kim SP, Frank I, Cheville JC et al. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J. Urol. 2012; 188; 405–409.
Linder BJ, Frank I, Cheville JC et al. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J. Urol. 2013; 189; 1670–1675.
Wang JK, Boorjian SA, Cheville JC et al. Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis. World. J. Urol. 2012; 30; 801–806.
Wasco MJ, Daignault S, Zhang Y et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 2007; 70; 69–74.
Daneshmand S. Determining the role of cystectomy for high‐grade T1 urothelial carcinoma. Urol. Clin. North Am. 2013; 40; 233–247.
Kamat AM. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J. Urol. 2006; 175; 881–885.
Amin MB, Ro JY, el‐Sharkawy T et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am. J. Surg. Pathol. 1994; 18; 1224–1232.
Nassar H, Pansare V, Zhang H et al. Pathogenesisofinvasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod. Pathol. 2004;17:1045–1050.
Mercogliano MF, Inurrigarro G, De Martino M et al. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2‐positive breast cancer. BMC Cancer 2017; 17; 895.
Ross JS, Wang K, Gay LM et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin. Cancer Res. 2014; 20; 68–75.
Ching CB, Amin MB, Tubbs RR et al. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual‐color in situ hybridization. Mod. Pathol. 2011; 24; 1111–1119.
Schneider SA, Sukov WR, Frank I et al. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod. Pathol. 2014;27:758–764.
Tschui J, Vassella E, Bandi N et al. Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer. Virchows Arch. 2015; 466; 703–710.
Willis DL, Flaig TW, Hansel DE et al. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol. Oncol. 2014; 32; 826–832.
Kamat AM, Gee JR, Dinney CP et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J. Urol. 2006; 175(3 Pt 1); 881–885.
Bertz S, Wach S, Taubert H et al. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radio chemotherapy. Virchows Arch. 2016; 469; 339–344.
Al‐Ahmadie HA, Iyer G, Lee BH et al. Frequentsomatic CDH1 loss‐of‐function mutations in plasmacytoid variant bladder cancer. Nat. Genet. 2016; 48; 356–358.
Keck B, Stoehr R, Wach S et al. The plasmacytoid carcinoma of the bladder–rare variant of aggressive urothelial carcinoma. Int. J. Cancer 2011; 129; 346–354.
Nigwekar P, Tamboli P, Amin MB et al. Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am. J. Surg. Pathol. 2009;33:417–424.
Dayyani F, Czerniak BA, Sircar K et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J. Urol. 2013; 189; 1656–1661.
Kaimakliotis HZ, Monn MF, Cheng L et al. Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. Urology 2014; 83; 1112–1116.
George J, Lim JS, Jang SJ et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015; 524; 47–53.
Shen P, Jing Y, Zhang R et al. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics. Oncogene 2018; 37; 3039–3044.
Kim PH, Cha EK, Sfakianos JP et al. Genomic predictors of survival in patients with high‐grade urothelial carcinoma of the bladder. Eur. Urol. 2015; 67; 198–201.
Beltran H, Prandi D, Mosquera JM et al. Divergent clonal evolution of castration‐resistant neuroendocrine prostate cancer. Nat. Med. 2016; 22; 298–305.
Centers for Medicare & Medicaid Services. Clinical laboratory improvement amendments (CLIA). 2022 https://www.cms.gov/regulations‐andguidance/legislation/clia/index.html.
U.S. Food & Drug Administration. FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. 2019 https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fdagrants‐accelerated‐approval‐erdafitinib‐metastatic‐urothelial‐carcinoma.
U.S. Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). 2022 https://www.fda.gov/medical‐devices/vitro‐diagnostics/listcleared‐or‐approved‐companion‐diagnostic‐devices‐vitro‐and‐imagingtools.
Voutsadakis IA. Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies. Curr. Oncol. 2022; 29; 1390–1407.
Cormedi MCV, Van Allen EM, Colli LM. Predicting immunotherapy response through genomics. Curr. Opin. Genet. Dev. 2021; 66; 1–9.
Matsushita H, Vesely MD, Koboldt DC et al. Cancer exome analysis reveals a T‐cell dependent mechanism of cancer immunoediting. Nature 2012; 482; 400–404.
Marabelle A, Fakih M, Lopez J et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open‐label, phase 2 KEYNOTE‐158 study. Lancet Oncol. 2020; 21; 1353–1365.
Marcus L, Fashoyin‐Aje LA, Donoghue M et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden‐high solid tumors. Clin. Cancer Res. 2021; 27; 4685–4689.
Loriot Y, Necchi A, Park SH et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 2019; 381; 338–348.
Rosenberg JE, O'Donnell PH, Balar AV et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti‐programmed death 1/programmed death ligand 1 therapy. J. Clin. Oncol. 2019; 37; 2592–2600.
Carlo MI, Ravichandran V, Srinavasan P et al. Cancer susceptibility mutations in patients with urothelial malignancies. J. Clin. Oncol. 2020; 38; 406–414.
Metcalfe MJ, Petros FG, Rao P et al. Universal point of care testing for lynch syndrome in patients with upper tract urothelial carcinoma. J. Urol. 2018; 199; 60–65.
Pradere B, Lotan Y, Roupret M. Lynch syndrome in upper tract urothelial carcinoma: significance, screening, and surveillance. Curr. Opin. Urol. 2017; 27; 48–55.
Scherrer E, Kang A, Bloudek LM, Koshkin VS. HER2 expression in urothelial carcinoma, a systematic literature review. Front. Oncol. 2022; 12; 1011885.
Patelli G, Zeppellini A, Spina F et al. The evolving panorama of HER2‐targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives. Cancer Treat. Rev. 2022; 104; 102351.
Zhao J, Xu W, Zhang Z et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta‐analysis. Int. Urol. Nephrol. 2015; 47; 87–94.
Gan K, Gao Y, Liu K, Xu B, Qin W. The clinical significance and prognostic value of HER2 expression in bladder cancer: a meta‐analysis and a bioinformatic analysis. Front. Oncol. 2021; 11; 653491.
Wolff AC, Hammond MEH, Allison KH et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J. Clin. Oncol. 2018; 36; 2105–2122.
Bartley AN, Washington MK, Ventura CB et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch. Pathol. Lab Med. 2016; 140; 1345–1363.